MedTrace Logo

Patient-Reported Outcomes in Real-life of Cabotegravir and Rilpivirine

NCT06403865 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 280

Last updated 2024-05-08

No results posted yet for this study

Summary

Context The introduction of the long-acting injectable antiretroviral treatment cabotegravir and rilpivirine into the therapeutic armamentarium for people living with HIV represents a potentially significant evolution in patients' experience of their treatment and pathology. Its effects on the quality of life of PLHIV are explored in this research. In addition, the two-monthly intra-muscular injection regimen also raises questions about the city-to-hospital transition of care for PLHIV, as well as compliance with the therapeutic window.

Main objective To evaluate the effect of switching HIV treatment to CAB+RPV LA on health-related quality of life on the "Treatment Impact" dimension of the PROQOL-HIV questionnaire, 15 months after switching treatment.

Population People living with HIV-1 whose ARV treatment has been changed to an injectable CAB+RPV LA treatment

Study Design Observational study. Inclusion at HIV medical follow-up visit for change of ARV treatment to CAB/RPV.

Self-administered questionnaires at M3, M9 and M15 after change of treatment (first CAB/RPV injection).

Conditions

  • Quality of Life

Interventions

DRUG

Cabotegravir, Rilpivirine Drug Combination

Treatment switch to CAB+RPV LA

Sponsors & Collaborators

  • Hopital Foch

    collaborator OTHER

  • University Paris 7 - Denis Diderot

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-31
Primary Completion
2026-04-30
Completion
2026-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06403865 on ClinicalTrials.gov